Cardiac drug sales: Who’s on top & who’s slipping

AstraZeneca led the pack of pharmaceutical companies for revenue from cardiovascular drugs in 2014, according to a PMLive analysis. But of the top 10 companies, only Bayer and Takeda posted growth in sales that year. Here are figures for the leading companies.

Candace Stuart, Contributor

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."